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Background: Statins are known to reduce cardiovascular morbidity and mortality in primary and secondary prevention
studies. Subsequently, a number of nonrandomised studies have shown statins improve clinical outcomes in patients
with heart failure (HF). Small randomised controlled trials (RCT) also show improved cardiac function, reduced
inflammation and mortality with statins in HF. However, the findings of two large RCTs do not support the evidence
provided by previous studies and suggest statins lack beneficial effects in HF. Two meta-analyses have shown statins do
not improve survival, whereas two others showed improved cardiac function and reduced inflammation in HF. It
appears lipophilic statins produce better survival and other outcome benefits compared to hydrophilic statins. But the
two types have not been compared in direct comparison trials in HF.
Methods/design: We will conduct a systematic review and meta-analysis of lipophilic and hydrophilic statin therapy in
patients with HF. Our objectives are:
1. To determine the effects of lipophilic statins on (1) mortality, (2) hospitalisation for worsening HF, (3) cardiac function
and (4) inflammation.
2. To determine the effects of hydrophilic statins on (1) mortality, (2) hospitalisation for worsening HF, (3) cardiac
function and (4) inflammation.
3. To compare the efficacy of lipophilic and hydrophilic statins on HF outcomes with an adjusted indirect comparison
meta-analysis.
We will conduct an electronic search of databases for RCTs that evaluate statins in patients with HF. The reference lists of
all identified studies will be reviewed. Two independent reviewers will conduct the search. The inclusion criteria include:
1. RCTs comparing statins with placebo or no statin in patients with symptomatic HF.
2. RCTs that employed the intention-to-treat (ITT) principle in data analysis.
3. Symptomatic HF patients of all aetiologies and on standard treatment.
4. Statin of any dose as intervention.
5. Placebo or no statin arm as control.
The exclusion criteria include:
1. RCTs involving cerivastatin in HF patients.
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2. RCTs with less than 4 weeks of follow-up.
Discussion: We will perform an adjusted indirect comparison meta-analysis of lipophilic versus hydrophilic statins in
patients with HF using placebo or no statin arm as common comparator.
Keywords: Lipophilic statin, Hydrophilic statin, Statin therapy, Adjusted indirect comparison, Heart failureBackground
Statins have been shown to decrease cardiovascular mor-
bidity and mortality in primary [1] and secondary [2]
prevention studies. The Cholesterol Treatment Trialists
(CTT) collaboration recently reported the findings of pro-
spective meta-analysis of individual data involving about
90,000 patients in 14 randomised trials. Statin therapy was
found to reduce the 5-year incidence of major vascular
events (defined as coronary death, non-fatal myocardial in-
farction, coronary revascularisation or stroke) by about one
fifth per every 1.0 mmol/l reduction in low-density lipopro-
tein cholesterol (LDL-C), regardless of the initial lipid pro-
file or other presenting characteristics [3]. The CTT
collaboration subsequently reported a further reduction in
the incidence of heart attack, coronary revascularisation
and ischaemic stroke with an additional 1.0mmol/l reduc-
tion of LDL-C. The authors also found that a 2–3 mmol/l
reduction of LDL-C would reduce the risk of vascular
events by about 40–50% [4]. The most recent meta-
analysis of 175,000 patients in 27 randomised trials indi-
cates that in individuals with a 5-year risk of major vascular
events lower than 10%, each 1 mmol/l reduction in LDL
cholesterol produced an absolute reduction in major vas-
cular events of about 11 per 1,000 over 5 years [5]. These
studies clarified the role of statin therapy in the prevention
of cardiovascular events and have shown that the benefits
of statin therapy exceed any known risks. Nonetheless, it is
still unclear whether statins are beneficial in patients with
established heart failure. A number of non-randomised
studies have shown statin therapy improves clinical out-
comes in patients with HF [6-10]. Likewise, small-scale
RCTs have shown improved cardiac function and reduced
inflammation and mortality outcomes in HF [11-14]. The
improved outcomes may be attributed to the cholesterol-
lowering effects of the statins, but are more plausibly asso-
ciated with their pleotropic effects.
In contrast to the non-randomised and small randomised
trials, the findings of two recent large RCTs—the Con-
trolled Rosuvastatin Multinational Study in Heart Failure
(CORONA) [15] and Gruppo Italiano per lo Studio della
Sopravvivenza nell’Insufficienza cardiaca (GISSI-HF) [16]—
do not seem to fully support the previous studies. Both tri-
als failed to show significant benefit in primary outcomes
compared with placebo. However, the CORONA reported
a significant reduction in hospital admissions. It is also re-
assuring to note that post hoc analyses of CORONA showsignificantly improved survival in patients with low con-
centrations of galectin-3 [17] and NT-proBNP [18] from
rosuvastatin treatment. Nonetheless, these findings do not
recommend the general use of statins in HF but endorse
their use in ischaemic heart disease patients with plasma
concentrations of galectin-3 and NT-proBNP lower than
19.0 ng/ml and 103 pmol/ml respectively. This observation
complements the findings of the Heart Protection Study
(HPS) in which patients with low levels of NT-proBNP had
improved survival with simvastatin treatment [19]. But the
presence of heart failure among study participants was not
recorded at baseline, making it impossible to directly esti-
mate the effect of simvastatin in patients with and without
heart failure at randomisation. This evidence comes from
retrospective analyses, which may thus be considered as
hypothesis generating and needs to be confirmed in a pro-
spective study. Furthermore, two meta-analyses of RCTs
[20,21] that randomised HF patients to statin or placebo
showed no significant improvement in survival. The find-
ings of CORONA and GISSI-HF coupled with those of the
two meta-analyses seem to weigh against the use of statin
therapy in HF. However, a closer examination of the trials
in the meta-analyses suggests that, in combining the data,
the researchers did not compare effects of statin types used
in the individual studies but treated them as if they were a
uniform class of drugs. Within the statins, there are two
distinct types identifiable by their lipophilicity. The type of
statin used in CORONA and GISSI-HF is believed to have
contributed to the unfavourable results in both trials and
also may have skewed the outcomes of both meta-analyses
towards the results of these two large trials.
Statins are similar in mode of action and comparable
in potency to reducing LDL-C; however, they differ in
exerting their pleotropic effects. Differences in pleotropic
effects are attributable to marked differences in lipophilicity
between the types of statins. This occurs because of the
presence or absence of polar moieties on their largely
hydrophobic structures, which influence solubility and lo-
calisation to bring about metabolic differences among the
statins [22]. Lipophilic statins enter into cells by passive dif-
fusion and are thus widely distributed in different tissues,
whereas hydrophilic statins are liver-specific, employ
carrier-mediated mechanisms for uptake and thus could re-
duce their ability to exert non-lipid effects on extrahepatic
tissues [23]. Atorvastatin, simvastatin, lovastatin, fluvastatin,
cerivastatin and pitavastatin are lipophilic, while pravastatin
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to exert more beneficial effects in patients with HF, though
equivocal outcomes have been reported in a few studies. In
contrast, the hydrophilic statins have generally shown more
unfavourable effects, though improved outcomes have
been reported in a few studies. In particular, hydrophilic
rosuvastatin, which is the most potent of all statins in redu-
cing LDL-C, is the statin used in the CORONA and GISSI-
HF trials. It is these large trials of a single hydrophilic statin
that overwhelm the meta-analyses.
Several studies, subsequent to CORONA and GISSI-HF,
have shown that statins may still improve survival and
other outcomes in patients with HF [24-26]. These studies,
though nonrandomised, again suggest that it is the lipo-
philic but not hydrophilic statins that may benefit patients
with HF [24]. In addition, a meta-analysis that failed to im-
prove overall survival with statin therapy showed in a sub-
group analysis that lipophilic statins may improve survival
in patients with HF [20]. Interestingly, two other meta-
analyses recently showed that statins improve cardiac func-
tion [27] and reduce inflammation [28] in patients with HF.
Inherent pharmacologic differences among statins may ac-
count for observed differences in clinical outcomes of pa-
tients. A close observation of these inconsistent and
conflicting data shows that the hydrophilicity or lipophilic-
ity of statins accounts for the controversial results obtained
in studies in HF. Several prospective and retrospective stud-
ies have compared the two types of statins in cardiovascular
conditions. The Pravastatin or Atorvastatin Evaluation and
Infection Therapy (PROVE-IT) study compared atorva-
statin 80 mg with pravastatin 40 mg in a head-to-head fash-
ion in patients with acute coronary syndrome. The
PROVE-IT study showed that lipid lowering with lipophilic
atorvastatin provides greater protection against death and
cardiovascular events than hydrophilic pravastatin although
the study did not employ equipotent doses of the two
statins [29]. A subanalysis of the Multicenter Study for Ag-
gressive Lipid-lowering Strategy by HMG-CoA Reductase
Inhibitors in patients with Acute Myocardial Infarction
(MUSASHI-AMI) database found hydrophilic pravastatin
to be superior to lipophilic statins in preventing new
Q-wave appearance and reducing cardiovascular events in
normocholesterolemic patients [30]. However, in a study of
patients with coronary artery disease, no significant differ-
ence in the incidence of all-cause events was observed with
the two types of statins [31]. Furthermore, a more recent
study has shown that short-term cardiovascular outcomes
were better with lipophilic statins, though long-term out-
comes were comparable to those of hydrophilic statins in
patients with acute myocardial infarction (AMI). Thus, sta-
tin type did not influence long-term outcomes in patients
with AMI [32].
However, in HF, little is known about differences in
the efficacy of the two types of statins, and it remainsunclear which statin type provides better survival and
other outcome benefits. Recently, hydrophilic rosuvastatin
has been shown to be superior to lipophilic simvastatin in
increasing plasma adiponectin and reducing HbA1c levels
in patients with non-ischaemic chronic heart failure on
standard therapy when compared in a randomised study.
Adiponectin is an adipocyte-specific cytokine that has key
metabolic effects including insulin sensitivity and predicts
cardiovascular events in patients with HF. Haemoglobin
A1c (HbA1c) level has been shown to be an independent
risk factor for mortality in diabetic and non-diabetic
patients with HF [33]. In another study, 63 stable HF out-
patients with dilated cardiomyopathy (DCM) on standard
therapy were randomised to either atorvastatin (n = 32) or
rosuvastatin (n = 31) and followed up for 6 months. Lipo-
philic atorvastatin was found to be superior to hydrophilic
rosuvastatin in improving cardiac sympathetic nerve activ-
ity and reducing plasma NT-proBNP levels in HF patients
with DCM [34]. However, these studies were not suffi-
ciently powered to detect significant differences in major
outcomes (survival and hospital admissions) in HF. Thus,
it remains unclear as to which type of statin—lipophilic or
hydrophilic—is more efficacious on outcomes of patients
with HF. As yet, there are no adequately powered head-to
-head comparison trials to compare the efficacy of the two
types of statins in HF. Thus, to compare the efficacy of
lipophilic and hydrophilic statins and to investigate which
statin subtype provides better survival and other outcome
benefits, we will review all available data from RCTs that
employed statins in the treatment of HF. We will subse-
quently conduct an adjusted indirect comparison meta-
analysis of the efficacy of lipophilic versus hydrophilic
statins in outcomes of HF.
Methods/Design
Study objectives
This review seeks to appraise the efficacy of lipophilic and
hydrophilic statins on clinical outcomes in heart failure and
to compare their efficacy using an adjusted indirect com-
parison meta-analysis. According to our protocol, the pri-
mary outcome is all-cause mortality. We will also examine
the effects of statins on cardiovascular mortality, sudden
death, hospitalisation for worsening HF, cardiac function
and markers of inflammation as secondary outcomes. We
will also evaluate the impact of follow-up and statin doses
on treatment outcomes in selected studies.
Inclusion criteria
Types of studies
Randomised controlled trials comparing statins with pla-
cebo or no statin in patients with symptomatic HF will be
our main inclusion criterion. Previous meta-analyses of
statins in HF will be included and a reference list of se-
lected meta-analyses will be searched. RCTs that employed
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will be eligible for this review.
Types of participants
Patients with symptomatic HF, regardless of the aeti-
ology, assigned to statin treatment or control (no statin
or placebo) and on standard medical therapy with at
least 1 month follow-up will be included in this review.
Type of interventions
1. Statin at any dose
2. Placebo or no statin as control
Types of outcome measures
All-cause mortality is an outcome of great importance in
HF and will provide the best estimate of treatment effect.
The effect of statin treatment on cardiovascular mortality,
sudden death, hospitalisation, cardiac function and markers
of inflammation will be evaluated.
Exclusion criteria
Trials involving cerivastatin in patients with HF will be
excluded. Cerivastatin has been withdrawn from the
market because of the increased incidence of rhabdo-
myolysis that led to kidney failure among patients who
received the full dose (0.8 mg/day) alone or with gemfi-
brozil [35]. Thus, inclusion of trials involving cerivastatin
in HF may introduce bias into the findings of the review.
Trials will be excluded if follow-up duration is less than
4 weeks. Trials with crossover designs and post hoc ana-
lysis of statins in HF trials will be excluded.
Search strategy
We will conduct an electronic search of PubMed,
MEDLINE, EMBASE, EBM review and Cochrane databases
from start dates to January 2013. Basic search terms from
combined text and Medical Subject Heading (MeSH) terms
including statin, heart failure, randomised controlled trials
(#statin AND #heart failure AND #randomised controlled
trials) will be used in varying combinations for the search.
Table 1 shows the main search strategy for PubMed. This
search strategy will be modified to suit each database. The
reference list of each identified study will be reviewed for
randomised studies. Two independent reviewers will per-
form the search.
A search diary will be kept detailing names of the data-
bases searched, keywords used and search results. Titles
and abstracts of studies to be considered for retrieval will
be recorded in EndNote reference software.
Selection procedures
Full-text articles identified by the search and meet the in-
clusion criteria, based on their title, abstract and subjectdescriptors will be obtained for data synthesis. Articles
identified through reference list searches will also be
considered for data collection. Two reviewers will inde-
pendently select articles according to inclusion criteria. In-
consistencies in selections will be resolved at a meeting
between the two reviewers prior to retrieval of selected ar-
ticles. Retrieved studies will be filed according to inclusion
and exclusion decisions. Quality of selected trials for in-
clusion in the review will be assessed. The Jadad quality
scale—a measure of study design that numerically
scores studies between 0 and 5 [36] —will be used to
evaluate the quality of selected trials. Here the two re-
viewers will independently assess studies for methodo-
logical validity prior to inclusion. Identified studies that
meet the inclusion criteria will then be grouped according
to the class of statin used in the trial. Figure 1 shows the
flow diagram of the study selection procedure.
Data collection and Statistical analysis
Following assessment of methodical quality, data will be
extracted from the identified papers. Data extraction will
be done by two reviewers and discrepancies will be re-
solved by a third reviewer. Data on the number of patients
randomised to active treatment, placebo or control, type
of statin, dose, loss to follow-up, level of blinding, conceal-
ment of allocation, specific study inclusion and exclusion
criteria, duration of follow-up, hospitalisation and deaths
will be abstracted from each study. Authors of selected
studies will be contacted for clarification when necessary.
Dichotomous outcome variables will be computed as
odd ratios (OR) with 95% confidence intervals (CIs) using
Peto’s one-step method for fixed-effects model [37]. From
previous meta-analysis, it is anticipated that most of the
eligible studies to be selected for this review will have
small sample sizes and may have no or similar events in
the control and experimental arms of studies. Thus, the
choice of Peto’s one-step approach will be the most appro-
priate method for our meta-analysis. For each study, the
“observed minus expected” statistic (O - E) and its vari-
ance (v) will be calculated from the number of participants
that had the dichotomous outcomes and the total number
of participants in each treatment arm. These (O - E)
values, one from every study, will be summed to produce
a grand total (Gt), with its variance (V) equal to the sum
of their separate variances. The value exp (Gt/V) is Peto’s
one-step estimate of the odds ratio, and its 95% confidence
interval will be exp (Gt/V ± 1.96/√V). For continuous out-
comes, endpoints will be based on the change from base-
line to follow-up. Pooled effects of continuous outcome
variables will be presented as standardised mean differ-
ences (SMD) with 95% CIs using the inverse variance
approach for the fixed-effects model. We anticipate sys-
tematic differences between the results of studies (hetero-
geneity); therefore, pooled effects estimates for both
Table 1 Search terms and strategy to search PubMed to
identify statin studies in heart failure
Strategy Search terms
#1 “Right-sided” OR “right sided”





#7 “Heart failure” OR “failure, heart”
#8 #7 AND (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#9 “Heart decompensation” OR “decompensation, heart”
#10 #8 OR #9
#11 ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical
trials[MeSH Terms] OR clinical trial[Publication Type] OR
random*[Title/Abstract] OR random allocation[MeSH Terms]
OR therapeutic use[MeSH Subheading])
#12 “Statin” OR “statins” OR “hydroxymethylglutaryl-CoA
reductase inhibitors”
#13 #12 AND #11 AND #10
Figure 1 Flow diagram of study selection procedure.
Bonsu et al. Systematic Reviews 2013, 2:22 Page 5 of 7
http://www.systematicreviewsjournal.com/content/2/1/22continuous and dichotomous outcomes will also be com-
puted with the random-effects approach of DerSimonian
& Laird [38].
In the absence of randomised trials sufficiently powered
to make head-to-head comparisons of lipophilic to hydro-
philic statins, an indirect comparison is plausible using a
common comparator (for this study, placebo or no statin
arm) [39-41]. Meta-analysis of trials comparing lipophilic
statins to control (placebo or no statin) will be conducted
to obtain an estimate of treatment effect. This will be pre-
ceded by a separate meta-analysis of trials comparing
hydrophilic statins to control. Statistical heterogeneity of
all pooled outcome measures in both meta-analyses will
be assessed with the I squared (I2) statistics (I2 > 50%;
treatment effect will be considered as statistically incon-
sistent) [42]. Meta-regression and subgroup analysis will
be performed to explore heterogeneity among selected tri-
als. The principle of meta-regression and subgroup ana-
lysis will be employed to evaluate the impact of several
moderators including patient age, sex, HF aetiology, sever-
ity of HF, different statin doses, baseline LDL cholesterol
and study follow-up duration on treatment outcomes of
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selected trials will be categorised into standard and inten-
sive dosage regimens. A meta-regression model will be
used to assess the impact of these moderators on treatment
outcomes in HF. We will perform sensitivity test to deter-
mine the robustness of the pooled estimates by exclusion
of one study at a time from the analysis. Publication bias
and small study effects will be assessed with the Begg’s
adjusted-rank correlation [43] and Egger’s regression asym-
metry tests [44]. To conduct an adjusted indirect compari-
son meta-analysis, the estimated difference in treatment
effect of lipophilic and hydrophilic statins in HF will be
determined by comparing the two estimated treatment ef-
fects using the Bucher’s approach [39]. All analyses will be
performed in the R statistical environment [45] and the
Indirect Meta-analysis Tool (METCARDIO, Turin, Italy).
Discussion
This study aims to provide evidence to show whether lipo-
philic statins are superior to hydrophilic statins on clinical
outcomes of heart failure. The lack of direct evidence from
head-to-head comparison of the two types of statins in pa-
tients with HF has necessitated our execution of an ad-
justed indirect comparison meta-analysis. Unlike other
methods, an adjusted indirect comparison employs a com-
mon comparator, which for this study is the placebo or no
statin arm of selected trials. This method ensures that the
within-trial randomisation is maintained and preserves
certain strengths of randomised allocation of patients for
estimating comparative effects of treatment [39,46], thus
minimising biases. In addition, results of indirect compari-
son of competing interventions appear to be consistent
with those of direct head-to-head comparison trials
[41,47]. To the best of our knowledge, this is the first in-
direct meta-analysis comparing the efficacy of lipophilic to
hydrophilic statins on clinical outcomes in patients with
HF to be performed. Although indirect comparisons can-
not replace evidence from direct comparison trials, it
could inform clinicians on choice of treatment among
competing interventions such as lipophilic and hydrophilic
statins in HF. Until randomised trials directly comparing
the two types of statins become available, indirect com-
parison may provide useful information to guide clinical
decision-making. At this time, we are unaware of any
planned studies to undertake such direct comparisons.
Thus, we will perform an adjusted indirect comparison of
lipophilic versus hydrophilic statins using placebo or no
statin arm as common comparator.
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